【 Direct Attack on the China International Expo 】 Experience the "Spillover Effect" of China International Expo, Geely's Second Exhibition Expands Its Moments in China
两把木椅狭
发表于 2023-11-9 12:00:15
1323
0
0
Xinhua Finance and Economics, Shanghai, November 9 (Reporter Du Kang) - Geely Science, a leading global biopharmaceutical company, has embarked on its second "journey to enter the international market" this year. From the "first time customer" who participated in the exhibition last year to the "repeat customer" who went to the CIIE again this year, Geely Science witnessed the rapid launch of drugs on display and witnessed the spillover effects brought by the CIIE. Geely Science stated that it looks forward to further expanding its "circle of friends" in China with the help of "Jinbo Magnetic Force".
In 2017, Geely officially began commercial operations in China, with drugs covering viral hepatitis, HIV prevention and treatment, as well as antifungal infections and tumors. At present, eleven innovative drugs have been approved in China, of which eight have been included in the national medical insurance catalog.
Jin Fangqian, Global Vice President and General Manager of Geely Science in China, said, "Last year, Geely participated for the first time and witnessed the spillover effects brought by the CIIE. We have personally witnessed the rapid launch of drugs on display. This year, when we go to CIIE again, we look forward to sharing Geely's rapid development and future plans in China with all sectors of society on such an open platform, accelerating the introduction of innovative products and continuously improving drug accessibility
It is worth mentioning that the innovative drug Tuodawei& Reg; And products in the field of antifungal agents, Anbisoft& Reg; Two drugs were first exhibited at the CIIE last year and have been successfully launched in China this year, rapidly achieving patient accessibility. This year's CIIE, Geely China comprehensively presented its "star" innovative drugs in the fields of HIV prevention and treatment, viral hepatitis, tumors, and antifungal agents.
In 2022, Gilead launched the construction of local research and development team and research and development capacity in China. In less than a year, it has promoted the rapid development of 14 Phase II/III clinical research projects, including 11 Phase II/III tumor clinical studies covering breast cancer, lung cancer, urogenital tumors, digestive tract tumors and gynecological tumors, and 3 anti-virus Phase III clinical studies. In addition, Geely also demonstrated plans to introduce innovative product indications for clinical research in China.
Thanks to the favorable policies of the country in promoting high-quality development and encouraging innovation, Geely has achieved rapid development since entering China for six years. "Jin Fangqian stated that China is one of Geely's three important strategic markets globally. Looking forward to further expanding the "circle of friends" of the medical ecosystem in China through the "Jinbo Magnetic Force".
The reporter learned that Geely will sign a series of contracts with China's ecological partners in the future, including signing a strategic cooperation memorandum with Jinyu Medical to assist in early diagnosis, treatment, and standardized treatment of diseases; Signed strategic cooperation memorandums with Shulan (Hangzhou) Hospital and Tunchang Branch of Hainan Provincial People's Hospital to support the prevention and treatment of viral hepatitis in Hangzhou and Hainan; Signed strategic cooperation with the Hainan Boao Lecheng International Medical Tourism Pilot Zone Management Bureau and Sichuan University West China Lecheng Hospital to promote the pilot trial of innovative drugs in the field of cancer in Boao.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- STMicroelectronics and Geely Automobile Group sign a long-term silicon carbide supply agreement and establish a joint laboratory
- How effective is the drug supply process initiated by Novo Nordisk for the approved slimming version of Smegglutide in China?
- "Weight loss pills" are sold in limited quantities in China? Novo Nordisk's latest response
- The weekly sales chart of Ideal Automobile has sparked controversy again, with NIO and Geely executives openly opposing it
- The weekly sales chart is causing controversy! NIO Xiaopeng Geely shouts its ideal message across the air
- Geely becomes the largest shareholder of Jixing Automobile, with both parties publicly responding for the first time
- Zeng Yuqun, owner of car 001! Baidu, Geely cooperate to set new car prices
- Yizi International expands its business in China and adds equity investment in Enxi Village
- Yizi International further expands its business in China and significantly increases its equity investment in Enxi Village
- Yizi International further expands its business in China and significantly increases its equity investment in Enxi Village
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 前天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 昨天 17:41
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 昨天 16:27
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 昨天 14:41
- 支持
- 反对
- 回复
- 收藏